HL7.XPROD.UV.GENDER-HARMONY\V2 Health Maintanence Example

HL7 Cross Paradigm IG: Gender Harmony - Sex and Gender Representation
1.0.0-ballot - ballot

This page is part of the HL7 Cross Paradigm IG: Gender Harmony - Sex and Gender Representation (v1.0.0-ballot: STU 1 Ballot 1) based on FHIR v5.0.0-ballot. . For a full list of available versions, see the Directory of published versions

V2 Health Maintanence Example

Registration of Name Change
Order of the PSA Laboratory Test
Result of the PSA Laboratory Test

Registration of Name Change

Using v2.9

MSH|^~\&|||||20220815151129||ADT^A01|Tw1244563214559JGX4U2p3hCLJH|P|2.9.1
EVN||20220815151118||01^Patient Event^HL70062
PID|1||patientID1^^^^MR||Smith^Jack^^^^^NOUSE~Smith^Julie^^^^^N||19700103
GSP|1|S||76691-5^Gender identity^LN|446151000124109^Male^SCT|19700103^20220801
GSP|2|S||76691-5^Gender identity^LN|446141000124107^Female^SCT|20220801
GSP|3|S||90778-2^Personal pronouns - Reported^LN|LA29518-0^He, Him, His, Himself^LN||20030201^20220801
GSP|4|S||90778-2^Personal pronouns - Reported^LN|LA29519-8^She, Her, Hers, Herself^LN|20220801
PV1||O

Using the pre-adoption profile in V2.5.1

MSH|^~\&|||||20220815151129||ADT^A01|Tw1244563214559JGX4U2p3hCLJH|P|2.5.1|||||||||GenderHarmony^^2.16.840.1.113883.9.282^ISO
EVN||20220815151118||01^Patient Event^HL70062
PID|1||patientID1^^^^MR||Smith^Jack^^^^^NOUSE~Smith^Julie^^^^^N||19700103
GSP|1|S||76691-5^Gender identity^LN|446151000124109^Male^SCT|19700103^20220801
GSP|2|S||76691-5^Gender identity^LN|446141000124107^Female^SCT|20220801
GSP|3|S||90778-2^Personal pronouns - Reported^LN|LA29518-0^He, Him, His, Himself^LN||20030201^20220801
GSP|4|S||90778-2^Personal pronouns - Reported^LN|LA29519-8^She, Her, Hers, Herself^LN|20220801
PV1||O

Order of the PSA Laboratory Test

Using v2.9

MSH|^~\&|||||20220815153129||OML^O21^OML_O21|Tw1244563asdderfd9JGX4U2p3hCLJH|P|2.9.1
PID|1||patientID1^^^^MR||Smith^Julie^^^^^N||19700103|
GSP|1|S||76691-5^Gender identity^LN|446141000124107^Female^SCT|20220801
GSP|2|S||90778-2^Personal pronouns - Reported^LN|LA29519-8^She, Her, Hers, Herself^LN|20220801
GSC|1|S||male^Male sex for clinical use^sexForClinicalUseCS||OBR^1||The patient has a prostate and is utilizing an estrogenic therapy regimen to suppress testosterone.
PV1||O
ORC|NW|911^ClinicOrderSystem|||||||20220815153120|||
PRT|by87765446t21h^ClinicOrderSystem|SP||OP^Ordering Provider^HL70912|^Jones^^^^^MD
OBR|1|911^ClinicOrderSystem||2857-1^Prostate specific Ag [Mass/volume] in Serum or Plasma^LN^^^^2.73

Using the pre-adoption profile in V2.5.1

MSH|^~\&|||||20220815153129||OML^O21^OML_O21|Tw1244563asdderfd9JGX4U2p3hCLJH|P|2.5.1|||||||||GenderHarmony^^2.16.840.1.113883.9.282^ISO
PID|1||patientID1^^^^MR||Smith^Julie^^^^^N||19700103|
GSP|1|S||76691-5^Gender identity^LN|446141000124107^Female^SCT|20220801
GSP|2|S||90778-2^Personal pronouns - Reported^LN|LA29519-8^She, Her, Hers, Herself^LN|20220801
GSC|1|S||male^Male sex for clinical use^sexForClinicalUseCS||OBR^1||The patient has a prostate and is utilizing an estrogenic therapy regimen to suppress testosterone.
PV1||O
ORC|NW|911^ClinicOrderSystem|||||||20220815153120|||^Jones^^^^^MD
OBR|1|911^ClinicOrderSystem||2857-1^Prostate specific Ag [Mass/volume] in Serum or Plasma^LN^^^^2.73

Result of the PSA Laboratory Test

Using v2.9

MSH|^~\&|||||20220816103129||ORU^Ro1^ORU_R01|Tw1244563asdderfd2mnhdyhshCLJH|P|2.9.1
PID|1||patientID1^^^^MR||Smith^Julie^^^^^N||19700103|
GSP|1|S||76691-5^Gender identity^LN|446141000124107^Female^SCT|20220801
GSP|2|S||90778-2^Personal pronouns - Reported^LN|LA29519-8^She, Her, Hers, Herself^LN|20220801
GSC|1|S||male^Male sex for clinical use^sexForClinicalUseCS||OBR^1||The patient has a prostate and is utilizing an estrogenic therapy regimen to suppress testosterone.
PV1||O
ORC|NW|911^ClinicOrderSystem|000051^LabInfoSystem||||||20220815153120|||
PRT|by87765446t21h^ClinicOrderSystem|SP||OP^Ordering Provider^HL70912|^Jones^^^^^MD
OBR|1|911^ClinicOrderSystem|000051^LabInfoSystem|2857-1^Prostate specific Ag [Mass/volume] in Serum or Plasma^LN^^^^2.73|||202208151601|||||||||||||||202208151745|||F
OBX|1|NM|2857-1^Prostate specific Ag [Mass/volume] in Serum or Plasma^LN^^^^2.73||3.0|ng/ml^NanoGramsPerMilliLiter^UCUM|0-4.0 ng/ml|N^Normal^HL70078|||F||||||||202208151741
PRT|123487689^LabInfoSystem|SP||PO^Performing Organization^HL70912||||Clinic Lab One
PRT|123487690^LabInfoSystem|SP||POMD^Performing Organization Medical DirectorHL70912|^Goodfellow^^^^^MD|||||||||123 Example Street^^Example City^CA^94133
NTE|1||Patients on testosterone suppressing medications, the upper limit of normal for the PSA should be reduced to 1.0 ng/ml
SPM|1|^14MP000051&LabInfoSystem||119364003^Serum specimen^SCT|||||||||||||202208151601|202208151601

Using the pre-adoption profile in V2.5.1

MSH|^~\&|||||20220816103129||ORU^Ro1^ORU_R01|Tw1244563asdderfd2mnhdyhshCLJH|P|2.5.1|||||||||GenderHarmony^^2.16.840.1.113883.9.282^ISO
PID|1||patientID1^^^^MR||Smith^Julie^^^^^N||19700103|
GSP|1|S||76691-5^Gender identity^LN|446141000124107^Female^SCT|20220801
GSP|2|S||90778-2^Personal pronouns - Reported^LN|LA29519-8^She, Her, Hers, Herself^LN|20220801
GSC|1|S||male^Male sex for clinical use^sexForClinicalUseCS||OBR^1||The patient has a prostate and is utilizing an estrogenic therapy regimen to suppress testosterone.
PV1||O
ORC|NW|911^ClinicOrderSystem|000051^LabInfoSystem||||||20220815153120|||^Jones^^^^^MD
OBR|1|911^ClinicOrderSystem|000051^LabInfoSystem|2857-1^Prostate specific Ag [Mass/volume] in Serum or Plasma^LN^^^^2.73|||202208151601|||||||||||||||202208151745|||F
OBX|1|NM|2857-1^Prostate specific Ag [Mass/volume] in Serum or Plasma^LN^^^^2.73||3.0|ng/ml^NanoGramsPerMilliLiter^UCUM|0-4.0 ng/ml|N^Normal^HL70078|||F||||||||202208151741||||Clinic Lab One|123 Example Street^^Example City^CA^94133
NTE|1||Patients on testosterone suppressing medications, the upper limit of normal for the PSA should be reduced to 1.0 ng/ml
SPM|1|^14MP000051&LabInfoSystem||119364003^Serum specimen^SCT|||||||||||||202208151601|202208151601